CANTREAT – Medical device or pharmaceutical?

A fundamental distinction is made between medical devices and drugs. By definition, medicinal products interfere with the body’s metabolism and immune system, i.e. they have a pharmacological effect. Cantreat merely serves as a “means of transport” for the pharmaceuticals defined by the attending physician and is therefore to be classified as a medical device. Of course, both pharmaceuticals and medical devices are subject to the relevant regulations and are strictly controlled.

Cantreat, as a “distribution method”, has the task of taking up the drug, transporting it to the desired place of use and, above all, keeping it there so that it can develop its full effect in a targeted manner. The Cantreat system components themselves have no pharmacological effect.

For the investor, this means that lengthy and cost-intensive approval procedures (up to 10 years), as are usually required for pharmaceuticals, are no longer necessary, so that a market launch can be achieved more quickly and the associated ROI can be achieved comparatively early.

The healing success depends largely on the choice of pharmaceuticals. Cantreat makes it possible to bring these to bear in the lowest dosage and in a very targeted manner in the area of application, while sparing the rest of the organism to a large extent.